NCT01234012View on ClinicalTrials.gov

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

March 31, 2014

Conditions
Solid Tumor
Interventions
BIOLOGICAL

IMF-001

subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.

Trial Locations (2)

10016

New York University (NYU) Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
lead

ImmunoFrontier, Inc.

INDUSTRY